Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus cetuximab beta and epcoritamab vs fruquintinib alone in third-line RAS/BRAF wild-type MSS colorectal cancer
ChiCTR2600123526Phase 4Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in colorectal adenocarcinoma comparing Fruquintinib + cetuximab beta + epcoritamab with Fruquintinib monotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
fruquintinibcetuximabepcoritamab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600123526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123526.